Jennifer Brogdon, PhD, Head of Cell and Gene Therapies in the Immuno-Oncology and Hematology Department at Novartis Institutes for Biomedical Research, will speak at Duke on Tuesday, April 22, for the Immunology Seminar Series in Jones 143 at 9:30 a.m. She is a 1996 alumna of Duke’s PhD program in immunology and completed her postdoctoral training at Yale University. Brogdon began her career at Novartis in 2004, where she has led numerous experimental cell therapy programs into clinical trials, including the first CAR-T therapy approved by the Food and Drug Administration. At Novartis, Brogdon leads a diverse, cross-functional team to develop next-generation CAR-T cell therapies.
The title of her talk is "Pioneering Innovation: Reimagining Cancer Treatment through Academic and Industry Collaboration.” The seminar is hosted by graduate students from the professional development committee of Duke Integrative Immunobiology.